The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Demerger of Oil and Gas Assets

18 Dec 2015 07:00

RNS Number : 5242J
Fastnet Equity PLC
18 December 2015
 

18 December 2015

 

Fastnet Equity plc

("Fastnet" or the "Company")

Demerger of Oil and Gas Assets

 

Highlights

· Transfer of the Company's existing oil and gas assets into a new company named Fastnet Hydrocarbons Limited ("Fastnet Hydrocarbons")

· Fastnet Hydrocarbons is held by a trust for the future benefit of shareholders of the Company (the "Hive out")

· Unsecured 4 year term loan granted for €660,000 to finance residual running costs of oil and gas assets

· Fastnet will no longer have any ongoing interest or further cost exposure in respect of oil and gas assets

 

Cathal Friel, Non-Executive Chairman, commented:

"Today's announcement positions Fastnet to focus exclusively on the Company's strategy of pursuing acquisition opportunities within the healthcare sector. 

"Ring-fencing the Company's existing oil and gas assets in a trust structure is designed to allow the search for a buyer of these oil and gas assets to continue.

"In the event that this search process is completed, the Company's existing shareholders would receive any value generated from the disposal of these assets."

 

Details of transaction

Fastnet Hydrocarbons has acquired from the Company, for an aggregate sum of £1, the entire issued share capital of two of Fastnet's subsidiaries being Fastnet Oil & Gas (Ireland) Limited ("FOGI") and Pathfinder Hydrocarbon Ventures Limited ("PHVL") which hold the Celtic Sea and Moroccan oil and gas assets and liabilities respectively. The shares in Fastnet Hydrocarbons have been transferred into a bare trust ("Trust") established for the benefit of shareholders on the register of the Company as at the close of business on 16 December 2015, pro rata to their shareholdings in Fastnet at that date. Cathal Friel has been appointed as director of Fastnet Hydrocarbons.

 

All investment of equity and debt in FOGI and PHVL was written down to nil in the audited accounts of Fastnet for the financial year ending 31 March 2015. All previous loans made by the Company to FOGI and PHVL have, to the extent not repaid out of cash reserves by FOGI or PHVL, been formally waived by Fastnet prior to the Hive Out, reflecting their impaired value.

 

Fastnet has made an unsecured 4 year term loan of an aggregate of €660,000 to FOGI and PHVL at an annual rate of interest of 4 per cent. above LIBOR in order that those entities are able to meet their respective obligations under the existing oil and gas licences and to facilitate an orderly winding down of FOGI and PHVL.

 

To the extent any future value is realised from Fastnet Hydrocarbons, FOGI and/or PHVL, the trustees of the Trust will arrange for any returns of capital or distributions made to it by Fastnet Hydrocarbons to be paid to beneficiaries of the Trust, being the current shareholders of Fastnet as described above. The terms of the loan require it to be settled in full, including all principal and accrued interest, immediately upon any change of control, disposal of business or all or substantially all of their assets or insolvency event of Fastnet Hydrocarbons (and each part of the loan made to FOGI and PHVL individually is immediately repaid on a change of control, disposal of the business or all or substantially all of their assets or insolvency event of FOGI and PHVL respectively). Fastnet Hydrocarbons, FOGI and PHVL all undertake not to pay any dividends or make any distributions to shareholders until the loan is repaid in full.

 

As a result of the Hive Out, Fastnet will no longer have any ongoing interest and will not have any further exposure to further costs that may be incurred in maintaining the licences within FOGI and PHVL.

 

Related Party Transaction

The acquisition of the shares in each of FOGI and PHVL by Fastnet Hydrocarbons constitutes a related party transaction under Rule 13 of the AIM Rules for Companies due to Cathal Friel's shareholding and role as director of both Fastnet and Fastnet Hydrocarbons. The independent directors consider, having consulted with the Company's Nominated Adviser, that the terms of the transaction are fair and reasonable in so far as the Company's shareholders are concerned.

 

For further information please contact:

Fastnet Equity plc

+353 (1) 644 0007

Cathal Friel, Non-Executive Chairman

Shore Capital

(Nomad & Joint Broker)

+44 (0) 20 7408 4090

Bidhi Bhoma, Edward Mansfield

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

Camarco

+44 (0) 20 3757 4980

Billy Clegg / Zoe Moulton

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGCAPUPAUQR
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.